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Abstract
Background Renal transplant patients have a high
peri-operative risk for cardiovascular events. Pre-op-
erative screening for cardiac ischaemia might lower
this risk, but there are no specific guidelines.
Methods We conducted a chart review for all renal
transplants performed between January 2010 and De-
cember 2013. We collected data about patient charac-
teristics, pre-operative cardiac evaluation before refer-
ral, diagnostic tests and interventions. Logistic regres-
sion analyses were then applied to relate these factors
to the composite endpoint of cardiac death, myocar-
dial infarction, coronary revascularisation or admis-
sion for heart failure within 3 months after transplan-
tation.
Results A total of 770 kidney transplants were per-
formed in 751 patients. In 750 cases (97%) a referral
to the cardiologist was made. Non-invasive ischaemia
detection by myocardial perfusion scintigraphy, exer-
cise stress test or dobutamine stress echocardiogra-
phy was carried out in 631 cases (82%). Coronary an-
giography was performed in 85 cases, which revealed
significant coronary artery disease in 19 cases. Pro-
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phylactic revascularisation was done in 7 cases. The
incidence of the study endpoint was 8.6%. In mul-
tivariable regression analysis, age at transplantation,
pre-transplant myocardial infarction or heart failure,
post-operative decrease in haemoglobin and positive
non-invasive ischaemia testing were significantly as-
sociated with the study endpoint. However, when
analysed separately, none of the different non-inva-
sive ischaemia detection modalities were related to
the study endpoint.
Conclusion Especially those renal transplant candi-
dates with a cardiac history carry a high risk for a car-
diovascular event post-transplantation. Uniformity
in cardiac screening of renal transplant candidates
and better pre-operative preparation might lower this
post-operative risk. Besides, post-transplant anaemia
should be prevented.
Keywords Cardiac screening · Kidney
transplantation · Non-invasive ischaemia detection ·
Coronary revascularisation
What’s new?
 Kidney transplantation should be considered
a high-risk procedure for post-operative cardiac
events.
 There are no specific guidelines for pre-operative
cardiac screening.
 Uniformity in cardiac screening of renal trans-
plant candidates, especially in ischaemia detec-
tion, is warranted.
 Pre-operative revascularisation does not seem to
be associated with a better outcome.
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Introduction
Patients with end-stage renal disease (ESRD) have
a high risk of cardiovascular events [1] and a low
quality of life [2, 3]. Patients with ESRD are often
asymptomatic, but the number of patients with sig-
nificant coronary artery stenosis (defined as stenosis
>50%) has been shown to be between 37% and 65%,
rendering them at high risk for short- and long-term
cardiovascular events or even death [4]. To lower this
cardiovascular risk and improve quality of life, kidney
transplantation can be performed in patients with
ESRD [5]. Despite a reduction in overall long-term
mortality with transplantation, an increased short-
term post-transplant cardiovascular mortality risk has
been documented [6]. For example, there is an in-
creased risk of type I myocardial infarction due to
plaque rupture because of changes in shear stress,
vasospasm and thrombocyte activation, but also of
type II myocardial infarction due to blood loss and
subsequent anaemia, tachycardia or hypotension [7].
Cardiac screening and pre-transplant treatment might
be helpful to lower the post-operative risk of cardio-
vascular events [8]. However, there is no consensus
on indications or methods for screening.
The European Society of Cardiology has published
guidelines on cardiovascular assessment and manage-
ment for non-cardiac surgery [9]. Kidney transplan-
tation is regarded as intermediate-risk surgery with
a relatively high threshold for ischaemia detection. Is-
chaemia detection is deemed appropriate only in pa-
tients with poor functional capacity or anginal com-
plaints, and more than one clinical risk factor. How-
ever, patients with renal failure display a poor cor-
relation between signs and symptoms and significant
coronary artery disease, and less frequently have angi-
nal complaints in the setting of acute or chronic is-
chaemia [10–12]. Therefore, clinical presentation of
ESRD patients may not be very helpful to distinguish
which patients should be screened. To avoid this,
screening can be determined by the number of risk
factors. Risk factors for cardiovascular disease in pa-
tients evaluated for renal transplantation were cap-
tured in the 2007 Lisbon Conference Report and in-
clude diabetes mellitus (DM), prior cardiovascular dis-
ease, >1 year on dialysis, left ventricular hypertrophy
(LVH), age >60 years, smoking, hypertension and dys-
lipidaemia [13]. The presence of three or more risk
factors should prompt testing [14, 15]. The majority
of renal transplant candidates have at least three of
these factors.
Current guidelines do not recommend a specific
screening test [9]. As many patients that undergo kid-
ney transplantation in this centre are referred from
peripheral hospitals and cardiac screening is per-
formed in the referring hospital, there is considerable
variation in screening tests used, depending upon
local expertise and experience. The most commonly
used tests are dobutamine stress echocardiography
(DSE), myocardial perfusion scintigraphy (MPS) or
exercise stress testing (EST). It is recommended to
first perform a non-invasive cardiac screening test,
because of the potential risks of coronary angiogra-
phy (CAG), including contrast nephropathy, bleeding
and cerebrovascular accident. Besides variation in the
screening method used, a lack of direct feedback on
cardiological complications after renal transplanta-
tion might hamper proper evaluation in the referring
hospital.
In the current study, we evaluated pre-operative
cardiac risk assessment and treatment. Furthermore,
we evaluated the incidence of cardiovascular events
within 3 months after transplantation and defined
predictors for these cardiovascular events.
Methods
Study population
This is a retrospective study of all consecutive kid-
ney transplants performed between 1 January 2010
and 31 December 2013at the Erasmus Medical Cen-
tre (EMC), Rotterdam. The kidney transplantation de-
partment of the EMC is the largest in the Netherlands,
performing about 200 deceased- or living-donor kid-
ney transplantations per year. Patients are referred by
the nephrology department of the EMC and from at
least six referring hospitals. Patients were excluded
from the study if they were <18 years of age or re-
ceived a combined liver-kidney transplant. All pa-
tients were followed up for 3 months or until trans-
plant failure or death, whichever came first. As every
transplant performed during the period was studied,
a patient could be included more than once. Com-
plete re-evaluation was performed before each new
registration as a transplant candidate. Study param-
eters were recorded for every new transplant in this
patient.
Study parameters
For all patients, all available clinical data were re-
viewed. Three or more risk factors were defined as
a binary variable including: DM, prior cardiovascu-
lar disease, prior heart failure, >1 year on dialysis,
LVH, age >60 years, smoking, hypertension and dys-
lipidaemia. History of dialysis and type and duration
of dialysis were recorded. Type of donor (living or
deceased) and delayed graft function (defined as the
need for at least one dialysis treatment in the 1st week
after kidney transplantation) were noted.
For all patients, pre-operative screening by the car-
diologist was recorded. Furthermore, if performed,
the results of ischaemia detection by EST, DSE and/or
MPS were documented. In some patients, only CAG
was performed; in others, CAG was done to further
evaluate the results of non-invasive ischaemia detec-
tion.
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Table 1 Patient characteristics
Variable All (n= 770) No cardiac event
(n= 704)
Cardiac event
(n= 66)
p a
Male gender 493 (64%) 452 (64%) 41 (62%) NS
Age at transplant (mean± SD) 54.3± 13.9 53.4± 14.0 63.0± 9.6 <0.001
Age above 60 309 (40%) 264 (38%) 45 (68%) <0.001
Delayed graft function 174 (23%) 149 (21%) 25 (38%) 0.001
Living donor 532 (69%) 499 (71%) 33 (50%) 0.001
Dialysis before kidney transplantation 522 (68%) 468 (66%) 54 (82%) 0.001
Dialysis duration longer than 1 year 374 (49%) 331 (47%) 43 (65%) 0.004
History of cardiac disease 139 (18%) 100 (14%) 39 (59%) <0.001
– Intervention 86 (11%) 62 (9%) 24 (36%) <0.001
– MI 81 (11%) 53 (8%) 28 (42%) <0.001
– Heart failure 46 (6%) 28 (4%) 18 (27%) <0.001
History of diabetes 186 (24%) 163 (23%) 23 (35%) 0.049
History of stroke 79 (10%) 67 (10%) 12 (18%) 0.03
History of peripheral artery disease 56 (7%) 43 (6%) 13 (20%) <0.001
History of smoking 146 (18%) 136 (19%) 10 (15%) NS
History of hypertension 678 (88%) 622 (88%) 56 (85%) NS
History of LVH 82 (11%) 74 (11%) 8 (12%) NS
History of hypercholesterolaemia 338 (44%) 313/702 (45%) 25/65 (38%) NS
Three or more risk factors 465 (60%) 407 (53%) 58 (88%) <0.001
Non-invasive ischaemia testing
– Abnormal MPS 93/279 (33%) 69/241 (29%) 24/38 (62%) <0.001
– Abnormal EST 9/328 (3%) 8/302 (3%) 1/26 (4%) NS
– Abnormal DSE 1/64 (2%) 1/61 (2%) 0/3 (0%) NS
Coronary angiography 85 (11%) 75 (11%) 10 (15%) NS
Significant CAD on angiography 19 (2%) 18 (3%) 1 (2%) NS
Difference in haemoglobin level (mmol/l, mean± SD) –2.2± 1.0 –2.1± 1.0 –2.6± 1.0 <0.001
All data are n (%) unless stated otherwise
Tx transplantation, MI myocardial infarction, LVH left ventricular hypertrophy, MPS myocardial perfusion scintigraphy, EST exercise stress testing, DSE dobu-
tamine stress echocardiography, CAD coronary artery disease
aNo cardiac event versus cardiac event
Events
The primary endpoint was defined as a composite of
cardiac death, myocardial infarction, coronary revas-
cularisation or heart failure necessitating admission
within 3 months after transplantation. The time frame
of 3 months was chosen as most complications post-
transplantation (bleeding, sepsis, rejection, restart
haemodialysis) occur within 3 months after trans-
plantation. Cardiac death was defined as death with
a clear cardiac cause or death of an unknown cause.
Only deaths with a documented non-cardiac cause
were classified as non-cardiac death. The fourth uni-
versal definition of myocardial infarction was used,
i.e. a rise and/or fall of cardiac troponin values with
at least one value above the 99th percentile upper
reference limit in combination with at least one of
the following: (1) symptoms of myocardial ischaemia;
(2) new ischaemic ECG changes; (3) development
of pathological Q waves; (4) imaging evidence of
new loss of viable myocardium or new regional wall
motion abnormality in a pattern consistent with an
ischaemic aetiology; (5) identification of a coronary
thrombus by angiography at autopsy. Pre- and post-
operative troponin levels or post-operative ECGs are
assessed only upon clinical indication. Coronary
revascularisation was defined as percutaneous coro-
nary intervention (PCI) or coronary artery bypass graft
(CABG) of any coronary artery. Heart failure necessi-
tating admission was defined as the need to treat heart
failure with intravenous diuretic, inotropic agent or
vasodilator in combination with symptoms and signs
of heart failure. All suspected primary endpoints were
adjudicated by a single nephrologist (M.S.) and cardi-
ologist (W.D.), who reached a consensus in discrepant
transplant candidates.
Statistical analyses
Categorical data are presented as numbers with per-
centages and the differences between the patients
with and without study endpoint were evaluated us-
ing chi-square tests. Continuous data are presented
as mean± standard deviation and differences between
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Fig. 1 Results of screen-
ing for coronary artery dis-
ease (CAD). CAG coronary
angiography, CABG coro-
nary artery bypass graft,
CTCA computed tomog-
raphy coronary angiog-
raphy, DSE dobutamine
stress echocardiography,
EST exercise stress testing,
MPS myocardial perfusion
scintigraphy, PCI percuta-
neous coronary intervention
770 Kidney transplant candidates
750 Candidates referred for cardiac screening 20 Candidates not screened
119 Candidates no 
ischaemia detection
631 Candidates  
ischaemia detection
328 Candidates EST
279 Candidates MPS
64 Candidates DSE
5 Candidates CTCA
9 Positive
93 Positive
1 Positive
1 Positive
19 Signiﬁcant 
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2 PCI
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these samples were tested using Student’s t-tests. Uni-
variable and multivariable logistic regression analyses
were applied to study the relation between a broad
range of patient characteristics (see Tab. 1) and the
study endpoint. The number of variables (degrees
of freedom) in the multivariable model was limited
to 7, since there were only 66 patients who reached
the study endpoint. Therefore, pragmatically, only
variables with a p-value <0.05 in univariable analysis
entered the multivariable stage, whereas the model re-
duction method of backward elimination was utilised,
again applying the p-value <0.05 criterion. For all
tests, a p-value <0.05 (two-sided) was considered sta-
tistically significant. Analyses were performed using
SPSS version 23 (IBM, Armonk, NY, USA).
Results
Baseline characteristics
A total of 770 kidney transplants were performed in
751 patients. There were no missing values for trans-
plant candidates. Mean age at time of transplantation
was 54± 14 years and the majority were men (64%)
(Tab. 1). Almost all patients had at least one risk fac-
tor (98%), including hypertension (88%), longer than
1 year on dialysis (49%), hypercholesterolaemia (44%)
and age above 60 years (40%). In 58% of transplant
candidates at least three risk factors were present. The
cardiologist was consulted pre-operatively in 97% of
transplant candidates.
Screening for coronary artery disease
Screening for significant coronary artery disease
(CAD) was performed in 631 transplant candidates
(82% of all cases); see Fig. 1. In 546 (87%) trans-
plant candidates only non-invasive ischaemia test-
ing was performed, in 18 (3%) only CAG was per-
formed without any non-invasive ischaemia testing,
and in 67 (11%) CAG was performed after non-inva-
sive ischaemia testing. Transplant candidates with-
out testing for CAD were younger (46.6 vs 55.9 years,
p< 0.001), significantly less often hadDM (14% vs 26%,
p= 0.001), had less often been on dialysis for longer
than 1 year (38% vs 51%, p=0.005) and less often
had three or more risk factors (46% vs 64%, p< 0.001).
There was no difference in gender, LVH, hypertension,
hypercholesterolaemia or current smoking.
Non-invasive testing
Non-invasive ischaemia testing was performed in 613
transplant candidates (80% of all cases). In 63 of
those (10%), two non-invasive ischaemia detection
modalities were used. Themost commonly performed
non-invasive test was EST (48.5%), followed by MPS
(41.3%). DSE (9.5%) and computed tomography coro-
nary angiography (CTCA) (0.7%) were used in only
a low number of cases.
328 ESTs: 47 ESTs were inconclusive (14.3%), 272
were negative for ischaemia (82.9%) and 9 were posi-
tive for ischaemia (2.7%). There were 47 inconclusive
ESTs, which were followed by 18 MPSs, 6 DSEs and
1 CTCA. Inconclusive ESTs were not followed by ade-
quate testing in 47% (22/47) of transplant candidates.
Of those retested, 4 MPSs were positive for reversible
ischaemia. Also, 28 MPSs and 3 DSEs were performed
in the group with a negative EST. This resulted in an-
other 9 divergent MPSs, 5 with reversible ischaemia
and 4 with irreversible ischaemia; no DSE was posi-
tive for ischaemia. Three positive ESTs were followed
by MPSs, of which only 1 was positive for reversible
ischaemia.
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Fig. 2 Screening for coro-
nary artery disease (CAD)
in transplant candidates
with a cardiac event af-
ter kidney transplantation.
CAG coronary angiography,
CABG coronary artery by-
pass graft,DSE dobutamine
stress echocardiography,
EST exercise stress testing,
MPS myocardial perfusion
scintigraphy
66 Candidates reached primary endpoint, all pre-operavely screened by cardiologist
60 Candidates (91%) ischaemia detecon
11 Candidates CAG
6 Candidates (9%) no ischaemia detecon
26 Candidates EST (1 posive)
38 Candidates MPS 
3   Candidates negave DSE
11 Permanent defect
12 Reversible defect
15 No abnormalies
1 CABG
4 Atherosclerosis without obstrucve CAD
15 Normal coronaries
279 MPSs: 186 MPSs were negative for ischaemia
(66.7%) and 93MPSs were abnormal (33.3%), 59 show-
ing reversible ischaemia and 34 irreversible ischaemia.
64 DSEs: Only 1 DSE was positive for ischaemia
(1.6%). In 3 negative DSEs, MPS was performed in
addition, leading to 1 positive MPS for reversible
ischaemia.
5 CTCA: One CTCA was suspected for significant
CAD (20%), the remaining 4 being negative (80%).
The suspected CTCA was followed by MPS, which
showed no ischaemia.
Coronary angiography
CAG was performed in 85 transplant candidates, in
18 transplant candidates without preceding non-in-
vasive ischaemia testing, in 29 transplant candidates
after negative ischaemia testing and in 38 trans-
plant candidates after positive ischaemia testing. In
19 transplant candidates there was significant CAD,
in 2 without non-invasive ischaemia testing, in 6 with
a negative test, and in 11 with a positive test. Posi-
tive non-invasive ischaemia testing prior to CAG or
three or more risk factors were not predictors for
significant CAD, compared to negative or no testing
(p= 0.18 and p= 0.1 respectively). In 7 of 19 transplant
candidates with significant CAD, revascularisation
was performed electively, 5 times CABG and 2 times
PCI. In 3 additional transplant candidates, PCI was
performed after approval for kidney transplantation
because of an acute coronary syndrome (ACS) while
on the waiting list for kidney transplantation. Two of
those 3 patients had negative ESTs and 1 patient had
reversible ischaemia on MPS but no significant CAD
on CAG.
Primary endpoint
The primary endpoint was reached in 66 patients
(8.6%, see Fig. 2). There were 4 cardiac deaths;
49 transplant candidates with post-operative ACS,
of whom 9 were subsequently revascularised; and
13 transplant candidates with an episode of heart fail-
ure requiring admission and medication. All patients
reaching the primary endpoint had been consulted by
the cardiologist pre-operatively. In 60 patients (91%)
screening for CAD was performed. Non-invasive is-
chaemia detection was performed in 58 patients:
49 patients underwent one test, while 9 patients
underwent two tests. There were 24 patients with
positive non-invasive ischaemia testing (1 EST and
24 MPSs), of whom 9 were referred for CAG. Two
additional patients underwent CAG without non-in-
vasive ischaemia detection. Of the 11 patients that
underwent CAG, only 1 had significant CAD (after
positive MPS) and was referred for CABG. Sensitivity
for MPS was 77% and specificity 41%, and for EST
33% and 75% respectively.
Of all transplant candidates with non-invasive is-
chaemia testing, 103 were positive for ischaemia
(16.8%). Transplant candidates with a positive non-
invasive ischaemia test had significantly more events
than patients with a negative test (24% vs 6%, p<0.001)
or no non-invasive ischaemia test (24% vs 5%, p< 0.001).
When the non-invasive ischaemia tests were analysed
separately, only transplant candidates with a diver-
gent MPS, but not DSE, CTCA or EST, had significantly
more events than transplant candidates with normal
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Table 2 Multivariate anal-
ysis
Variable RR 95% confidence interval p
Age at transplant (per year increase) 1.04 1.0–1.1 0.005
History of MI 4.3 2.3–8.3 <0.001
History of heart failure 5.4 2.5–11.4 <0.001
Positive non-invasive ischaemia testing 2.6 1.4–5.1 0.01
Haemoglobin difference (per mmol decrease) 1.5 1.2–2.0 0.003
MI myocardial infarction, RR relative risk
or no MPS (26% vs 8%, p<0.001 and 26% vs 6%,
p< 0.001).
Tab. 1 shows that patients that reached the pri-
mary endpoint more often received a deceased-donor
kidney transplant (p=0.001), more often had a cardio-
vascular history (59% vs 14%, p< 0.001), more often
had DM (35% vs 23%, p= 0.049), were more often
older than 60 years (68% vs 38%, p<0.001), and were
more often on dialysis longer than 1 year (65% vs 47%,
p= 0.004). Also they more often had three or more
clinical risk factors (88% vs 53%, p<0.001), more often
had delayed graft function (38% vs 21%, p= 0.001),
more often had a larger decrease in haemoglobin
post-operatively (–2.1± 1 vs –2.6± 1, p< 0.001) and
more often had abnormal MPS (62% vs 29%, p< 0.001).
There were no differences in gender, smoking habit,
LVH, hypertension, hypercholesterolaemia, positive
EST, DSE or CTCA.
In multivariable analysis, history of myocardial in-
farction (p< 0.001), history of heart failure (p< 0.001),
age at transplantation (p=0.005), difference in haemo-
globin level (p=0.003) and any positive non-invasive
ischaemia testing (p=0.01) remained as significant
predictors of the study endpoint (Tab. 2). Analysis
of the influence of MPS separately failed to reach
significance in multivariable analysis (p=0.08).
Discussion
The main finding of this study is that in 8.6% of renal
transplant patients, there was a cardiovascular event
within 3 months after transplantation. These events
occurred despite pre-transplant cardiac evaluation in
almost all patients and screening for significant CAD
in 82% of patients and the incidence is higher than the
predicted 1–5% (intermediate) risk for 30-day mortal-
ity or myocardial infarction in the European Society of
Cardiology (ESC) guideline for non-cardiac surgery. Of
the patients that reached the study endpoint, 60% had
negative pre-operative non-invasive ischaemia testing
and were subsequently accepted for renal transplan-
tation. Sensitivity for MPS and EST was 77% and 33%
respectively, while specificity was 41% and 75% re-
spectively. DSE was not performed in enough trans-
plant candidates to reliably determine sensitivity and
specificity. Non-invasive tests for CAD have a lower
sensitivity and specificity in patients with renal fail-
ure than in the general population. In populations
with chronic kidney disease stage 5, DSE and MPS had
sensitivities varying from 0.44 to 0.89 and 0.29 to 0.92
and specificities ranging from 0.71 to 0.94 and 0.67 to
0.89, respectively, for identifying 1 or more coronary
stenoses >70% [15]. The reason for the decreased sen-
sitivity and specificity in the population with ESRD
might be that the target heart rate has not been at-
tained because of a bad physical condition, anaemia
or the use of beta-blockers. Although positive non-
invasive ischaemia tests in ESRD patients show poor
correlation with significant CAD, both positive DSE
and MPS have been associated with cardiac death and
myocardial infarction, both while on the waiting list
and post-transplantation [16, 17]. We also found that,
of all four non-invasive ischaemia tests, MPSwas most
prevalent in the population with a cardiac event post-
transplantation. However, in multivariable analysis,
no single non-invasive ischaemia detection modality
was able to predict cardiovascular events after kidney
transplantation. When analysed together, any posi-
tive non-ischaemia detection test was correlated with
a post-transplant cardiovascular event. This could be
explained by the inconsistency in the tests used and
the use of tests that are non-discriminatory in this
population.
Non-invasive ischaemia testing was the only pre-
dictor of a cardiovascular event that can be influenced
by the cardiologist, the others being age and history
of myocardial infarction or heart failure. Therefore,
it seems important not only to use uniform testing
but also a better test. Very recently, Winther and co-
workers showed that in 154 patients with ESRD, eval-
uated for kidney transplantation, MPS was not a pre-
dictor of major adverse cardiovascular events (MACE)
or death [18]. However, they showed for the first time
that CTCA significantly predicted MACE and death.
Furthermore, they were able to identify a group with
a low risk of MACE and mortality, namely patients
with less than three risk factors and a coronary artery
calcium score (CACS) of less than 400. Based on their
findings they propose an interesting new algorithm of
a combination of risk factors and CACS and subse-
quent CTCA for cardiac screening in renal transplant
candidates.
In order to reduce cardiovascular complications
peri-operatively, patients with significant CAD should
be adequately treated. In our study, of 103 positive
non-invasive ischaemia tests only 35 were followed
by CAG (6 positive ESTs, 24 MPSs with reversible is-
chaemia, 5 MPSs with irreversible ischaemia). Most
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pre-transplant cardiac evaluations are performed in
the referring hospital, so we do not know why CAG
was performed in such a low number of cases after
positive ischaemia detection. On CAG, 19 patients
had significant CAD (22%), of whom 7 were revascu-
larised and 12 were managed medically. Eventually,
10 patients (only 1.3% of all transplant candidates)
were revascularised, as 3 additional patients expe-
rienced an ACS while on the waiting list and were
revascularised. There was no difference in primary
endpoint between medically managed or revascu-
larised patients, but the numbers are low and of
course patients are not randomised, so probably the
selection of worse patients was treated.
Routine prophylactic revascularisation before low-
and intermediate-risk surgery in patients with proven
CAD is not recommended in the ESC guideline on
cardiovascular assessment and management for non-
cardiac surgery (class III, level of evidence B). This
recommendation is based upon the CARP study [19],
in which patients with significant CAD that were
scheduled for elective major vascular surgery were
randomised to pre-operative revascularisation or no
revascularisation. Pre-operative revascularisation
did not alter long-term outcome. The 1992 study
by Manske and co-workers is the only randomised
controlled trial that evaluated coronary revascular-
isation in renal transplant candidates [20]. A total
of 26 asymptomatic insulin-dependent diabetic pa-
tients were randomised to revascularisation or medi-
cal treatment. Ten of 13 medically managed and 2 of
13 revascularised patients had a cardiovascular end-
point with a median follow up of 8.4 months. Manske
et al. concluded that diabetic renal transplant candi-
dates should be screened for silent CAD, as coronary
revascularisation might decrease cardiac morbidity
and mortality. These results must be interpreted
with caution as medically treated patients were only
treated with a calcium channel blocking drug and
acetylsalicylic acid, which is nowadays thought to be
inadequate. Since then, several observational studies
have been published with mixed results. In a study by
de Lima et al., 44% of 519 pre-transplant patients had
significant CAD on CAG. Most patients were treated
conservatively, while only 13% had a cardiac interven-
tion (at the discretion of the attending cardiologist).
No difference was found in cardiac-event-free and pa-
tient survival between the patients with and without
an intervention [21]. In a later study, de Lima et al.
showed that patients with significant CAD (>70%
stenosis) experienced more coronary events com-
pared to patients with less significant lesions. There
was no difference in mortality or events between pa-
tients treated medically or by intervention, although
severity of CAD in the latter was higher [22]. In con-
trast, in a retrospective analysis, Kahn et al. showed
that patients with medically managed obstructive
CAD had significantly higher rates of death at 5 years
post-transplantation when compared to those who
were revascularised before transplantation [23]. In
a pre-kidney transplant population in London, Kumar
et al. showed excellent survival rates and low compli-
cation rates after revascularisation with an aggressive
intervention protocol. Renal transplant candidates
demonstrated 1- and 3-year survival rates of 98.0%
and 88.4% in those who underwent revascularisation
and then transplantation, 75.0% and 37.1% in those
who did not undergo revascularisation or transplan-
tation, and 94.0% and 90.0% in those who underwent
revascularisation and remained on a transplant list
[24]. Overall, cardiovascular intervention before renal
transplantation has not unanimously been shown to
reduce the prevalence of cardiovascular disease (CVD)
after transplantation. However, these results must be
considered with caution because, by definition, pa-
tients referred for intervention had more serious and
widespread disease than those on medical treatment
because referral was at the discretion of the local
cardiologist. This means that the CVD-free survival
of the population on medical treatment should have
been far better because they were a selection of pa-
tients with less severe disease. Nonetheless, at best,
the results were comparable or even worse.
The current study has some limitations. First, this
is a retrospective study and therefore only an asso-
ciation and no causation can be extracted from the
results. Secondly, many patients were screened by
cardiologists from referring hospitals and we had ac-
cess only to the correspondence from the cardiolo-
gist. Therefore, we did not judge the results of non-
invasive ischaemia testing and CAG ourselves. Thirdly,
the cohort under study dates from 2010 to 2013, but
we believe that the results are still valid as ischaemia
detection methods have not changed since then and
cardiovascular events post-transplantation have not
decreased.
Conclusion
In conclusion, in this retrospective study we showed
that the risk of experiencing a myocardial event after
kidney transplantation is high for an elective proce-
dure and higher than the intermediate risk according
to the ESC guidelines. This risk was predicted by age,
pre-transplant myocardial infarction or heart failure,
post-operative decrease in haemoglobin and positive
non-invasive ischaemia testing. There was a trend
for MPS to predict cardiovascular events post-trans-
plantation, while CAG did not. However, the CAG
was performed in only a low number of cases. Pre-
transplant revascularisation did not prevent cardio-
vascular events post-transplantation, although again
the numbers are very low. These results are in line
with those of earlier studies and show the complexity
of cardiac screening in renal transplant candidates.
A prospective randomised controlled study to un-
ravel the indications, methods and consequences of
ischaemia detection (i.e. with or without revascu-
Predictors of postoperative cardiovascular complications up to 3 months after kidney transplantation
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larisation) could provide insight into how to prevent
cardiovascular events post-transplantation.
Conflict of interest W.K. den Dekker, M.C. Slot, M.M.L. Kho,
T.W. Galema,J. van de Wetering, E. Boersma and J.I. Roodnat
declare that they have no competing interests.
Open Access This article is licensed under a Creative Com-
mons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in
anymedium or format, as long as you give appropriate credit
to the original author(s) and the source, provide a link to
the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article
are included in the article’sCreativeCommons licence, unless
indicated otherwise in a credit line to thematerial. If material
is not included in the article’s Creative Commons licence and
your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permis-
sion directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. GansevoortRT,Correa-RotterR,HemmelgarnBR, JafarTH,
Heerspink HJ, Mann JF, et al. Chronic kidney disease
and cardiovascular risk: epidemiology, mechanisms, and
prevention. Lancet. 2013;382(9889):339–52.
2. Lowrie EG, Curtin RB, LePain N, Schatell D. Medical out-
comes study short form-36: a consistent and powerful
predictor of morbidity and mortality in dialysis patients.
AmJKidneyDis. 2003;41(6):1286–92.
3. MapesDL,LopesAA,SatayathumS,McCulloughKP,Good-
kin DA, Locatelli F, et al. Health-related quality of life as
a predictor of mortality and hospitalization: the Dialysis
OutcomesandPracticePatternsStudy(DOPPS).KidneyInt.
2003;64(1):339–49.
4. Lentine KL, Hurst FP, Jindal RM, Villines TC, Kunz JS,
Yuan CM, et al. Cardiovascular risk assessment among
potential kidney transplant candidates: approaches and
controversies. AmJKidneyDis. 2010;55(1):152–67.
5. Meier-KriescheHU, Schold JD, Srinivas TR, ReedA, Kaplan
B.Kidney transplantationhalts cardiovasculardiseasepro-
gression in patients with end-stage renal disease. Am J
Transplant. 2004;4(10):1662–8.
6. Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial in-
farction and kidney transplantation. J Am Soc Nephrol.
2006;17(3):900–7.
7. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert
JS. Perioperative myocardial infarction. Circulation.
2009;119(22):2936–44.
8. HartA,WeirMR,KasiskeBL.Cardiovascularriskassessment
inkidneytransplantation. KidneyInt. 2015;87(3):527–34.
9. KristensenSD,Knuuti J, SarasteA, Anker S, BotkerHE,Hert
SD, et al. ESC/ESAGuidelinesonnon-cardiac surgery: car-
diovascular assessment and management: The Joint Task
Force on non-cardiac surgery: cardiovascular assessment
and management of the European Society of Cardiology
(ESC) and the European Society of Anaesthesiology (ESA).
EurHeartJ.2014;35(35):2383–431.
10. De Lima JJ, Sabbaga E, Vieira ML, de Paula FJ, Ianhez LE,
KriegerEM,etal. Coronaryangiographyisthebestpredictor
of events in renal transplant candidates compared with
noninvasivetesting.Hypertension. 2003;42(3):263–8.
11. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M.
Clinical characteristics of dialysis patients with acute my-
ocardial infarction in the United States: a collaborative
project of the United States Renal Data System and the
National Registry of Myocardial Infarction. Circulation.
2007;116(13):1465–72.
12. Sosnov J, Lessard D, Goldberg RJ, Yarzebski J, Gore JM.
Differentialsymptomsofacutemyocardial infarctioninpa-
tientswithkidneydisease: acommunity-wideperspective.
AmJKidneyDis. 2006;47(3):378–84.
13. Abbud-FilhoM, Adams PL, Alberu J, Cardella C, Chapman
J, Cochat P, et al. A report of the Lisbon Conference on the
care of the kidney transplant recipient. Transplantation.
2007;83(8Suppl):S1–S22.
14. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman
RH, Roth D, et al. The evaluation of renal transplantation
candidates: clinical practice guidelines. Am J Transplant.
2001;1(Suppl2):3–95.
15. LentineKL,Costa SP,WeirMR,Robb JF, Fleisher LA,Kasiske
BL, et al. Cardiac disease evaluation and management
among kidney and liver transplantation candidates: a sci-
entificstatement fromtheAmericanHeartAssociationand
the AmericanCollege of Cardiology Foundation. J AmColl
Cardiol. 2012;60(5):434–80.
16. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ.
Prognosticvalueofmyocardialperfusionstudiesinpatients
with end-stage renal diseaseassessed for kidneyor kidney-
pancreas transplantation: a meta-analysis. J Am Soc
Nephrol. 2003;14(2):431–9.
17. Wong CF, Little MA, Vinjamuri S, Hammad A, Harper JM.
Technetium myocardial perfusion scanning in prerenal
transplant evaluation in the United kingdom. Transplant
Proc. 2008;40(5):1324–8.
18. Winther S, Svensson M, Jorgensen HS, Rasmussen LD,
Holm NR, Gormsen LC, et al. Prognostic value of risk
factors, calciumscore,coronaryCTA,myocardialperfusion
imaging, and invasive coronary angiography in kidney
transplantation candidates. JACC Cardiovasc Imaging.
2018;11(6):842–54.
19. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski
WC, Littooy F, et al. Coronary-artery revascularization
before elective major vascular surgery. N Engl J Med.
2004;351(27):2795–804.
20. Manske CL, Wang Y, Rector T, Wilson RF, White CW.
Coronary revascularisation in insulin-dependent di-
abetic patients with chronic renal failure. Lancet.
1992;340(8826):998–1002.
21. DeLima JJ,GowdakLH,dePaulaFJ, ArantesRL, deOliveira
AL,RamiresJA,etal. Treatmentofcoronaryarterydiseasein
hemodialysis patients evaluated for transplant—a registry
study. Transplantation. 2010;89(7):845–50.
22. DeLimaJJ,GowdakLH,dePaulaFJ,MuelaHC,David-Neto
E, Bortolotto LA. Coronary artery disease assessment and
intervention in renal transplantpatients: analysis fromthe
KiHeartcohort. Transplantation. 2016;100(7):1580–7.
23. Kahn MR, Fallahi A, Kim MC, Esquitin R, Robbins MJ.
Coronary artery disease in a large renal transplant popu-
lation: implications for management. Am J Transplant.
2011;11(12):2665–74.
24. Kumar N, Baker CS, Chan K, Duncan N, Malik I, Frankel
A, et al. Cardiac survival after pre-emptive coronary
angiography in transplant patients and those awaiting
transplantation. ClinJAmSocNephrol. 2011;6(8):1912–9.
Predictors of postoperative cardiovascular complications up to 3 months after kidney transplantation
